Approves

• The FDA has approved new COVID-19 vaccines for the 2026-2027 season, specifically designed to target the XFG variant. • The vaccines are approved for adults aged 65 and older, with eligibility extended to younger individuals in high-risk groups depending on the specific shot. • This update is critical for maintaining immunity against evolving strains and protecting vulnerable populations during the upcoming respiratory virus season.

• The FDA has approved updated COVID-19 vaccines designed to protect against the latest circulating strains of the virus. • Health officials emphasize that these vaccines are most effective at preventing severe disease, hospitalizations, and ICU admissions. • High-risk groups, including pregnant women and individuals with diabetes, asthma, cancer, or heart and mental health conditions, are strongly encouraged to get vaccinated.

• The FDA has approved a landmark drug designed to treat pancreatic cancer, one of the deadliest forms of the disease. • The medication utilizes a new therapeutic approach by blocking a specific protein that fuels tumor growth in the vast majority of pancreatic cancer cases. • This approval is significant because the drug has demonstrated a measurable ability to improve patient survival rates.

• The U.S. has approved daraxonrasib, a breakthrough drug designed to treat pancreatic cancer, which is widely regarded as one of the most serious and difficult-to-treat malignancies. • Unlike traditional chemotherapy, this medication specifically targets the activated KRAS protein found within pancreatic cancer cells to inhibit tumor growth. • Clinical trial data involving medical oncologist Kyaw Lwin Aung indicates that the drug is highly effective, doubling the survival time for patients.

• The US Food and Drug Administration (FDA) approved updated Covid-19 vaccines on Thursday to target the dominant XFG variant. • This regulatory decision enables manufacturers to immediately begin shipping the new doses to doctors' offices and pharmacies nationwide. • The update is critical for maintaining immunity against evolving strains, though uncertainty persists regarding how insurance providers will cover the costs.

Decision allows manufacturers to begin shipping doses, but confusion remains about insurance coverageThe US Food and Drug Administration approved updated Covid-19 vaccines on Thursday, allowing manufacturers to begin shipping doses to pharmacies and doctors’ offices across the country.The FDA approved Moderna, Novavax-Sanofi and Pfizer-BioNTech’s updated Covid vaccines, the companies ⁠said on Thursday, ⁠after ​an advisory panel recommended that the shots should target ⁠the dominant XFG variant. Continue reading...

• The FDA has approved a novel regimen featuring iberdomide, a cereblon E3 ligase modulator (CELMoD), for the treatment of relapsed/refractory multiple myeloma (RRMM). • The treatment, used in combination with daratumumab and dexamethasone, is specifically effective for patients who have previously failed immunomodulatory drugs like lenalidomide and pomalidomide. • Approval was supported by data from the phase 3 EXCALIBER-RRMM trial focusing on minimal residual disease (MRD) negativity rates, following an NDA acceptance on February 17, 2026.